世界の粘性補充市場の規模、シェア、トレンド分析レポート – 業界の概要と 2031 年までの予測

粘性サプリメント市場分析

粘性補充療法市場は、効果的な疼痛管理ソリューションを必要とする変形性関節症やその他の関節疾患の増加に牽引され、大幅な成長を遂げています。粘性補充療法では、関節にヒアルロン酸 (HA) を注入して潤滑性を高め、疼痛を軽減し、可動性を高めます。最近の製剤技術の進歩により、より効果的で長持ちする粘性補充療法製品が開発され、患者の多様なニーズに応えています。たとえば、新しい架橋技術とバイオエンジニアリングされた HA 製品の導入により、これらの注射剤の粘度と弾力性が向上し、患者の転帰が改善されています。さらに、粘性補充療法の利点に関する医療専門家の認識が高まっており、臨床診療での採用が促進されています。オンライン プラットフォームを含む流通チャネルの拡大により、これらの治療法が患者にとってより利用しやすくなっています。さらに、粘性補充療法と他の治療法を統合した併用療法の継続的な研究により、市場の成長がさらに促進されると予想されます。全体的に、粘性補充療法市場は、技術革新と関節関連の病気に対する効果的な解決策を求める患者数の増加に支えられ、継続的な拡大が見込まれます。

粘性サプリメント市場規模

世界の粘性補充療法市場規模は、2023年に15億3,000万米ドルと評価され、2024年から2031年の予測期間中に8.50%のCAGRで成長し、2031年までに29億4,000万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

粘性補充療法の市場動向

「単回注射製剤への好感度の高まり」

粘性補充療法市場は、効果的な疼痛管理ソリューションを必要とする変形性関節症やその他の関節疾患の増加により、大幅な成長を遂げています。世界の粘性補充療法市場における顕著な傾向の 1 つは、従来の複数回注射レジメンよりも単回注射製剤が好まれるようになっていることです。このような変化は、主に患者の利便性とコンプライアンスによって推進されており、単回注射製品により、医療提供者への複数回の通院の必要性が軽減されます。たとえば、膝の変形性関節症に対する単回注射ヒアルロン酸治療薬である Durolane の導入は、その有効性と患者に提供する利便性により人気を博しています。さらに、整形外科治療における低侵襲処置への重点が高まっていることから、これらの革新的なソリューションの需要が高まっています。変形性関節症や関節痛に対する効果的で便利な治療を求める患者が増えるにつれて、単回注射粘性補充療法製品の採用により、世界市場で大幅な成長が促進され、患者の満足度と治療結果が向上すると予想されます。

レポートの範囲と粘性補充市場のセグメンテーション       

粘性補充市場の定義

粘性補充療法は、ゲル状の物質（通常はヒアルロン酸）を関節腔（最も一般的には膝）に注入する医療処置です。この処置は、関節液の粘性と弾力性を回復するように設計されており、変形性関節症や関節損傷を患っている人の関節を滑らかにし、痛みを軽減し、可動性を改善します。粘性補充療法は、クッション性を与え、関節機能を強化することで、変形性関節症の患者の不快感を軽減し、全体的な生活の質を向上させることを目的としています。

粘性サプリメント市場の動向

ドライバー

• 高齢化人口の増加

人口の高齢化に伴い、重度の外傷により入院する高齢患者の数も増加しています。加齢に伴う健康問題、特に膝関節症の増加により、診断と治療の両方の選択肢に対する需要が高まっています。高齢者人口の増加は医療制度にさらなる圧力をかけ、膝関節症、およびサルコペニア、骨粗鬆症、骨減少症などの関連疾患を予防・管理するためのより効果的なケア、サービス、技術が必要となります。高齢者は特にこれらの病気にかかりやすく、骨や関節が弱くなります。このような場合、患者に即時かつ効果的な緩和を提供するために粘性補充療法がますます利用されています。その結果、変形性関節症の有病率が上昇し、早期診断の必要性が高まるにつれて、粘性補充療法による治療の需要は世界の医療環境において大幅に拡大しており、重要な市場推進力となっています。

• 骨粗鬆症と変形性関節症に対する感受性の上昇

Osteoporosis is a bone disease characterized by decreased bone mineral density and mass, along with changes in bone quality or structure, which increases the risk of fractures due to weakened bones. This condition is more prevalent in women, particularly post-menopausal women, who often experience fractures as osteoporosis is a silent disease that typically shows no symptoms. Elderly individuals are also at a higher risk for developing osteoporosis. In contrast, osteoarthritis is a joint disorder marked by inflammation of the joints and surrounding tissues, significantly impairing mobility. These silent conditions lead to weakened bones and joints, resulting in serious consequences such as spinal deformities, fractures, and sudden falls. Consequently, the rising prevalence of osteoporosis and osteoarthritis directly boosts the demand for viscosupplementation treatments aimed at addressing complications arising from these conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive growth in the global viscosupplementation market.

Opportunities

• Safety and Efficacy of Intra-Articular Hyaluronic Acid (IAHA)

Various types of hyaluronic acid injections, commonly referred to as viscosupplementation, are utilized for treating knee osteoarthritis. These injections are derived either from rooster or chicken combs or produced through bacterial fermentation, and they are administered directly into the joint. Intra-articular hyaluronic acid (IAHA) is an FDA-approved treatment for knee osteoarthritis, offering a localized therapeutic option that provides symptomatic relief without the systemic adverse effects commonly associated with intra-articular corticosteroids. Multiple randomized controlled trials (RCTs) and meta-analyses have evaluated the efficacy and safety of IAHA, yielding mixed findings. However, IAHA has been shown to positively impact pain management and improve joint function. In addition, there is growing evidence that multiple courses of IAHA can influence long-term outcomes, such as reducing the reliance on analgesics and delaying the necessity for total knee replacement surgery. This demonstrates a significant market opportunity for viscosupplementation, as the increasing adoption of IAHA in treatment regimens can enhance patient outcomes and expand the market.

• Increasing Investment in Research and Development (R&D)

Investment in research and development (R&D) for viscosupplementation is critical for exploring new applications and enhancing existing products, presenting significant market opportunities. As the understanding of joint health and the mechanisms of osteoarthritis evolves, R&D can facilitate the development of advanced formulations with improved efficacy and reduced side effects. For instance, ongoing research into bioengineered hyaluronic acid derivatives aims to create longer-lasting effects and better integrate with joint tissues, which could significantly improve patient outcomes. In addition, R&D efforts focused on combinations of viscosupplementation with other treatment modalities, such as platelet-rich plasma (PRP) therapy, are showing promising results in clinical trials. These advancements expand the therapeutic potential of viscosupplementation and attract investment and partnerships, ultimately enhancing market reach. Therefore, the commitment to R&D in the viscosupplementation sector represents a vital opportunity for growth and innovation in addressing joint disorders and improving patient care.

Restraints/Challenges

• Lack of Technical Expertise

Finding, attracting, and hiring talent is essential for building a skilled bench of engineers and technicians, but this process poses significant challenges. The manufacturing workforce is aging rapidly, leading to a wave of retirements, while the medical industry faces a shortage of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and those with undergraduate or postgraduate qualifications (engineers) remains high, the supply of qualified individuals is dwindling, particularly for complex procedures such as viscosupplementation that require trained professionals. Moreover, assembling a competent additive manufacturing (AM) workforce goes beyond recruitment; employees must continually update their skills as technology evolves. Many recent engineering graduates lack AM-specific training, making it difficult for employers to find candidates with the necessary expertise. This shortage of technical skills is thus a significant constraint on market growth.

• Stringent Government Regulations

The global commercialization of viscosupplementation by various key market players is contingent upon compliance with regulatory frameworks established in different countries. Pre-market approval processes for medical devices vary significantly across regions, with the U.S. Food, Drug, and Cosmetic Act (FD&C Act) governing medical devices in the United States, while the European Union oversees regulations in Europe. In addition, the rapid evolution of privacy policies and regulations in the Asia-Pacific and EMEA regions, including countries such as India, Russia, China, South Korea, Singapore, Hong Kong, and Australia, further complicates compliance. Viscosupplementation is regulated by a comprehensive structure of laws and guidelines designed to protect patients from potentially harmful treatments. While viscosupplementation serves as a vital intervention for damaged, injured, or infected body parts in cases of osteoarthritis and sports injuries helping to maintain patient mobility any misguidance in its application can jeopardize patient safety and bodily integrity. Therefore, the stringent rules and regulations governing the use of viscosupplementation may pose a significant challenge to market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Viscosupplementation Market Scope

The market is segmented on the basis of type, treatment, diagnosis, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

• Animal Origin
• Non-Animal Origin

Age Group

• Geriatric
• Adults

Injection

• Single Injection
• Three Injections
• Five Injections

Molecular Weight

• Intermediate Molecular Weight
• Low Molecular Weight
• High Molecular Weight

End User

• Hospital
• Orthopedic Clinics
• Ambulatory Care Centers
• Others

Distribution Channel

• Direct Tender
• Retail Sales

Viscosupplementation Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is leading the market primarily due to the presence of key players in the industry and its status as the largest consumer market, supported by a high GDP. The U.S. is projected to experience significant growth, driven by advancements in drug treatments and innovative healthcare technologies that enhance patient outcomes. In addition, a robust healthcare infrastructure and substantial investment in research and development further contribute to the region's dominance in the ear and nasal packing market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Viscosupplementation Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Viscosupplementation Market Leaders Operating in the Market Are:

• Anika Therapeutics, Inc. (U.S.)
• SEIKAGAKU CORPORATION (Japan)
• Bioventus (U.S.)
• Fidia Farmaceutici S.P.A (Italy)
• Ferring B.V (Netherlands)
• sanofi-aventis U.S. LLC (U.S.)
• Zimmer Biomet (U.S.)
• OrthogenRx, Inc. (a subsidiary of AVNS) (U.S.)
• APTISSEN (France)
• Johnson & Johnson Services, Inc. (U.S.)
• LG Chem. (South Korea)
• Viatris Inc. (U.S.)
• IBSA Institut Biochimique SA (Switzerland)
• Ortobrand International (U.S.)
• TRB CHEMEDICA SA (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Lifecore (a subsidiary of Landec Corporation) (U.S.)
• VIRCHOW BIOTECH (India)
• Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals) (India)

粘性補充市場の最新動向

• 2022年11月、関節保存医療を専門とする著名な企業であるアニカ・セラピューティクス社は、単一の主要評価項目に焦点を当てた第3相臨床試験を無事に完了しました。この薬は、重度の膝関節炎に苦しむ人々のために特別に設計されています。同社は現在、治療薬のFDA承認の取得と世界市場での使用許可の取得に注力しています。
• 2022年6月、ジョンソン・エンド・ジョンソンは、第3相試験から得られた新たな知見を発表し、同社の薬剤で治療した患者は、活動性乾癬性関節炎を管理しながら、2年間にわたってより良好で一貫した長期的成果を経験したことを実証した。
• 2022年5月、Fidia Farmaceutici SPAは、スペインで導入された革新的な製品ポートフォリオを通じて、ヒアルロン酸（HA）の再生特性をうまく活用しました。このポートフォリオは、さまざまな医療用途で組織の修復を強化し、治癒を促進することを目的としています。HAの独自の利点を活用することで、Fidiaは再生医療市場のリーダーとしての地位を確立しています。
• 2022年4月、コーレンライフはジュニパーバイオロジクスと提携し、膝関節炎の革新的な治療法であるTissueGene-C低用量の開発と商品化に着手しました。この治療は、単回の関節内注射で行われ、外科的介入を必要としません。
• 2021年5月、小野薬品工業株式会社と生化学工業株式会社は、関節機能を高めることを目的とした30mg関節内注射剤「ジョイクル」を発売しました。生化学工業は、2021年3月に日本でこの製品の製造販売承認を取得しました。

SKU-10709